NanoViricides is trading 5.21% higher at $1.51 after announcing that enrollment and dosing began in its Phase II oral NV-387 Ebola trial.
- The company announced the milestone on September 28, 2026; the first patients started dosing around September 23 in the Democratic Republic of Congo.
- The announcement did not explicitly attribute the share-price move to the news. Broader markets were lower amid rising oil prices and geopolitical concerns; no reliable live volume or activity-level figure was established.